Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.54 |
| ▸ | DRD3 | P35462 | 14/20 | 0.54 |
| ▸ | DRD4 | P21917 | 10/20 | 0.54 |
| ▸ | HTR1A | P08908 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | HTR7 | P34969 | 4/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633520 | 0.97 | DRD2 (0.59) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL16633535 | 0.83 | DRD2 (0.53) | DRD2DRD3DRD4HTR2AHTR7 | |
| SCHEMBL16633146 | 0.82 | KCNH2 (0.58) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL16633469 | 0.81 | DRD2 (0.59) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL3408350 | 0.81 | DRD2 (0.62) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL13499598 | 0.81 | DRD2 (0.51) | DRD2DRD3HTR2AHTR7 | |
| SCHEMBL16633399 | 0.80 | DRD2 (0.58) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL16634075 | 0.80 | KCNH2 (0.62) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL29785698 | 0.80 | DRD2 (0.64) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL16633483 | 0.78 | DRD2 (0.59) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238632-B2 | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | NHWA Pharma, Corporation (CN) | 2016-01-19 | — | — | US | claimed |
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-04-16 | — | — | US | claimed |
| US-9238632-B2 | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | NHWA Pharma, Corporation (CN) | 2016-01-19 | — | — | US | disclosed |
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | HTR5A, HTR3C, HTR3A | DRD2 80/4885DRD3 57/4885DRD4 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.